ADE Reporting Oversight To Receive Increased Agency Attention - FDAer
This article was originally published in The Tan Sheet
Executive Summary
Efforts to ensure drug manufacturers adhere to adverse drug experience reporting requirements will receive increased attention from FDA in the future, FDA New Jersey District Director Douglas Ellsworth said at the Nonprescription Drug Manufacturers Association Manufacturing Controls Seminar in Philadelphia Oct. 8-9.